INTRODUCTION: The National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) Quality of Life (QOL) Committee was initiated in 1986. PURPOSE: The purpose of this review is to describe the evolution of the Committee's work and to highlight key developments such as the formulation of a policy regarding health-related quality-of-life (HRQOL) assessment, the provision of guidelines to ensure completion of HRQOL data within the protocol requirements, the rationale behind the choice of HRQOL instruments, the timing of assessments and the development of data analytic methods. These developments are illustrated with examples from CTG studies. RECOMMENDATIONS: There is a lack of concordance between conventional toxicity data and HRQOL data and comparative studies designed to elucidate these differences are to be encouraged. Also, more studies are required to compare different analytic strategies and to determine how much missing data is acceptable, particularly in oncology studies where attrition is inevitable.
INTRODUCTION: The National Cancer Institute of Canada (NCIC) Clinical Trials Group (CTG) Quality of Life (QOL) Committee was initiated in 1986. PURPOSE: The purpose of this review is to describe the evolution of the Committee's work and to highlight key developments such as the formulation of a policy regarding health-related quality-of-life (HRQOL) assessment, the provision of guidelines to ensure completion of HRQOL data within the protocol requirements, the rationale behind the choice of HRQOL instruments, the timing of assessments and the development of data analytic methods. These developments are illustrated with examples from CTG studies. RECOMMENDATIONS: There is a lack of concordance between conventional toxicity data and HRQOL data and comparative studies designed to elucidate these differences are to be encouraged. Also, more studies are required to compare different analytic strategies and to determine how much missing data is acceptable, particularly in oncology studies where attrition is inevitable.
Authors: Bruno Kovic; Xuejing Jin; Sean Alexander Kennedy; Mathieu Hylands; Michal Pedziwiatr; Akira Kuriyama; Huda Gomaa; Yung Lee; Morihiro Katsura; Masafumi Tada; Brian Y Hong; Sung Min Cho; Patrick Jiho Hong; Ashley M Yu; Yasmin Sivji; Augustin Toma; Li Xie; Ludwig Tsoi; Marcin Waligora; Manya Prasad; Neera Bhatnagar; Lehana Thabane; Michael Brundage; Gordon Guyatt; Feng Xie Journal: JAMA Intern Med Date: 2018-12-01 Impact factor: 21.873
Authors: Felicity W K Harper; Elisabeth I Heath; Marci E J Gleason; Louis Penner; Patricia Lorusso; Ding Wang; Terrance L Albrecht Journal: J Cancer Ther Date: 2012-10
Authors: M Kröz; F Schad; M Reif; H B von Laue; G Feder; R Zerm; S N Willich; M Girke; B Brinkhaus Journal: Eur J Med Res Date: 2011-10-10 Impact factor: 2.175
Authors: Houda Bahig; Brandon G Gunn; Adam S Garden; Rong Ye; Kate Hutcheson; David I Rosenthal; Jack Phan; Clifton D Fuller; William H Morrison; Jay Paul Reddy; Sweet Ping Ng; Neil D Gross; Erich M Sturgis; Renata Ferrarotto; Maura Gillison; Steven J Frank Journal: Int J Part Ther Date: 2021-06-25
Authors: Rebecca Mercieca-Bebber; Michael J Palmer; Michael Brundage; Melanie Calvert; Martin R Stockler; Madeleine T King Journal: BMJ Open Date: 2016-06-15 Impact factor: 2.692